REV-ERB agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-05. Numbers and descriptions here follow the published literature rather than marketing material.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
The amount of octane in each sample is different, but the amount of nonane is the same (in practice this is not a requirement). Due to scaling, the areas of the nonane peak appear to have different areas, but in reality the areas are identical. Therefore, the relative amounts of octane in each sample increases in the order of mixture 1 (least) < mixture 3 < mixture 2 (most). This conclusion is reached because the ratio of the area of octane to that of nonane is the least in mixture 1 and the most, in mixture 2. Mixture 3 has an intermediate ratio. This ratio can be written as
They had planned to wed in summer 2020 but postponed the event twice due to the COVID-19 pandemic. At her wedding, Alizée wore the 1980s wedding dress belonging to Carole Middleton, her mother-in-law. The couple welcomed their first child, Inigo Gabriel, on 21 September 2023.
=== Amateur === Lisa has been weight training since 2003 and has been conditioning for competitive entry since 2008. She first really got into bodybuilding in 2006 while she was living in Japan while she was teaching English. Her boyfriend at the time was a Japanese bodybuilding champion and she started reading up on bodybuilding, such as Negrita Jayde, and started training with weights. In 2007, after she got married, she went to see the 2007 Ms. Olympia competition for their honeymoon and was impressed when she saw female bodybuilders for the first time. Former UK junior champion Lewis Breed oversees her training and pre-contest preparation for bodybuilding. She competed in her debut competition at the 2009 NABBA England, placing second place behind Jennie Ellam. She then competed at the 2009 NABBA Universe achieving second place to Larissa Cunha. Her best win was first place at the UKBFF British Championships, where she won the Ladies Physique class. On 19 March 2014, she announced that she had been awarded her IFBB pro card and can now compete as a pro.
Sources: en.wikipedia.org
Vivien Jess. Learning Centre Manager, Education Training Service. For services to Defence and to the community in Northern Ireland. Dr Terry Martin John. Lately General Practitioner, The Firs Medical Centre, London Borough of Waltham Forest and lately Chair of International Committee, British Medical Association. For services to Medicine. Frances Barbara Johnson. Learning Support Assistant, Dame Tipping Church of England Primary School, Romford, London Borough of Havering. For services to Education. Louis Connor Johnson. For services to the community in Wolverhampton, West Midlands. Hilary Johnston. Founder, Cwtch Baby Bank. For services to Mothers and Babies in South East Wales. Monica Ann Johnston. Admission/Discharge Co-ordinator, Neurosciences, Belfast Health and Social Care. For services to Nursing and to the community in Northern Ireland. Anne Jones. For services to the community in Neston, Cheshire. Patricia Ellen Jones. For services to the community in Nailsworth, Gloucestershire. Sundeep Kaur. Director, United Sikhs. For services to the community in the West Midlands during Covid-19. Lisa Michelle Kay. For charitable services to Ukrainian Refugees and to the community in Solihull, West Midlands. Coral June Kelham. For services to the community in Barrow upon Soar, Leicestershire. Anne Marie Kelly. Lately Regional Office Manager, Northern Ireland Organ Donor Service. For services to Organ Donation and Transplantation in Northern Ireland. Richard Kennell. Chief Executive Officer, SOFEA. For services to Social Inclusion and to Alleviating Food Poverty.
== Treatment == Though treatment of the different chronic wound types varies slightly, appropriate treatment seeks to address the problems at the root of chronic wounds, including ischemia, bacterial load, and imbalance of proteases. Periwound skin issues should be assessed and their abatement included in a proposed treatment plan. Various methods exist to ameliorate these problems, including antibiotic and antibacterial use, debridement, irrigation, vacuum-assisted closure, warming, oxygenation, moist wound healing (the term pioneered by George D. Winter), removing mechanical stress, and adding cells or other materials to secrete or enhance levels of healing factors. It is uncertain whether intravenous metronidazole is useful in reducing foul smelling from malignant wounds. There is insufficient evidence to use silver-containing dressings or topical agents for the treatment of infected or contaminated chronic wounds. For infected wounds, the following antibiotics are often used (if organisms are susceptible) as oral therapy due to their high bioavailability and good penetration into soft tissues: ciprofloxacin, clindamycin, minocycline, linezolid, moxifloxacin, and trimethoprim-sulfamethoxazole. The challenge of any treatment is to address as many adverse factors as possible simultaneously, so each of them receives equal attention and does not continue to impede healing as the treatment progresses.
== Pathology == Haptotaxis plays a role in several kinds of diseases where the movement or aggregation of cells causes the symptoms. As mentioned before, cancers that are metastatic have the ability to perform haptotaxis in order to spread throughout the body. This ability is not limited to tumor cells. Idiopathic pulmonary fibrosis (IPF) is a disease marked by fibrosis in lung mesothelial cells. TGF-β1 is a cytokine found in higher concentrations of lungs from patients who have IPF, and induces haptotaxis of pleural mesothelial cells. At the same time, TGF-β1 causes the mesothelial cells to develop into myofibroblasts, which contribute to the symptoms in IPF. The result is that there becomes an aggregation of myofibroblasts in the lungs, which leads to fibrosis of the mesothelial cells. During nephritis, VCAM-1 is expressed in higher levels on the tubules of nephrons, which leads to increased leukocyte migration via the gradient established by VCAM-1. This increased expression was not found on the capillary endothelial cells. This migration of leukocytes leads to inflammation and tissue destruction characteristic of an inflammatory response.
Sources: en.wikipedia.org
By micronizing progesterone, its particles are made smaller (mainly <10 μM) and its surface area is increased, thereby enhancing absorption from the intestines. Suspension and partial solubilization of progesterone in oil containing medium- to long-chain fatty acids likewise improves the bioavailability of oral progesterone. Progesterone is a lipophilic compound and it has been theorized that suspension of progesterone in oil may improve its absorption by the lymphatic system, thereby allowing a portion of oral progesterone to bypass the first pass through the liver and hence enhancing its bioavailability. Compared to plain milled progesterone, peak levels of progesterone following a single 200 mg oral dose were increased 1.4-fold by micronization, 1.2-fold by suspension in oil, and 3.2-fold by the combination of micronization and suspension in oil. Oral micronized progesterone suspended in oil is rapidly and almost completely absorbed from the intestines. There is wide interindividual variability in the bioavailability of oral progesterone. As progesterone was not used orally for many decades due to its poor bioavailability (until the introduction of oral micronized progesterone in oil-filled gelatin capsules in 1980), oral progestins (synthetic progestogens) with improved metabolic stability and high oral bioavailability were developed and have been used clinically instead. When oral progesterone is used at typical clinical dosages, only very low levels of progesterone are measured using reliable methods.
=== 6 June === A Libyan National Army (LNA) unit crossed the common border into Sudan and reached three kilometers within Sudanese territory near Jabal Arkanu before clashing with an SAF-allied group, leaving two Libyans dead and others captured.
Hydrogen peroxide is most commonly available as a solution in water. For consumers, it is usually available from pharmacies at 3 and 6 wt% concentrations. The concentrations are sometimes described in terms of the volume of oxygen gas generated; one milliliter of a 20-volume solution generates twenty milliliters of oxygen gas when completely decomposed. For laboratory use, 30 wt% solutions are most common. Commercial grades from 70% to 98% are also available, but due to the potential of solutions of more than 68% hydrogen peroxide to be converted entirely to steam and oxygen (with the temperature of the steam increasing as the concentration increases above 68%) these grades are potentially far more hazardous and require special care in dedicated storage areas. Buyers must typically allow inspection by commercial manufacturers.
=== Production === Production of nitro cold brew coffee begins with the making of cold brew coffee. Once the grounds are adequately steeped, the coffee is poured into a room-temperature bottle or keg. As the cold brew is poured into a cup, it is charged with nitrogen to give it a rich, creamy head of foam, similar to draft beer. (Though most beers and soft drinks are charged with carbon dioxide, nitrogen is occasionally used in darker stouts, resulting in a smoother finish.) Nitro cold brew is typically served chilled but without ice, which would damage the foamy top.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.